Physiologically Based Pharmacokinetic Model to Assess the Influence of Blinatumomab-Mediated Cytokine Elevations on Cytochrome P450 Enzyme Activity

Blinatumomab is a CD19/CD3 bispecific T-cell engager (BiTE®) antibody construct for treatment of leukemia. Transient elevation of cytokines (interleukin (IL)-6, IL-10, interferon-gamma (IFN-γ)) has been observed within the first 48 hours of continuous intravenous blinatumomab infusion. In human hepa...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Y, Hijazi, Y, Wolf, A, Wu, B, Sun, Y-N, Zhu, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4592530/
https://www.ncbi.nlm.nih.gov/pubmed/26451330
http://dx.doi.org/10.1002/psp4.12003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4592530/
https://www.ncbi.nlm.nih.gov/pubmed/26451330
http://dx.doi.org/10.1002/psp4.12003

Ejemplares similares